AVAN: CEO Discusses Licensing & Development Agreement w/Pfizer for CDX-110
[?]
Submitted By Knobias ClipReport
Shares of AVANT Immunotherapeutics, Inc. (AVAN) surged on Thursday after the Company announced a licensing and development agreement with Pfizer. Pfizer will be granted an exclusive worldwide license to a therapeutic cancer vaccine candidate, CDX-110, in Phase 2 development for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer. This agreement also gives Pfizer exclusive rights to the use of EGFRvIII vaccines in other potential indications.
